At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Avelumab +1 morebiological
Likely dose
Avelumab 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-label, Single Arm, Multicenter Study of Avelumab With Hypofractionated Radiation in Adult Subjects With Transformed IDH Mutant Glioblastoma
In Brief
A Phase 2 clinical trial evaluating Avelumab and Hypofractionated radiation therapy (HFRT) for Glioblastoma. Completed, enrolled 6 participants across 4 sites.
Detailed Summary
The purpose of this study is to test how safe and effective treatment with the combination of Avelumab and radiation is for IDH mutant gliomas that have transformed to glioblastoma after chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesUnited States
CollaboratorsEMD Serono
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartMar 2017
Primary CompletionAug 2019
TodayJul 2026
First PostedNov 21, 2016
Enrollment StartMar 17, 2017
Primary CompletionAug 29, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.6 years ago
Interventions
Avelumabbiological
Avelumab 10 mg/kg intravenously (IV) every 2 weeks
Hypofractionated radiation therapy (HFRT)radiation
Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions